RECOVEREEZ FORTE – Clinical Study

Know More

Scientific Evidence

Interactive Research School for Health Affairs, (IRSHA)

Study Title: Evaluation of Recovereez Forte capsules

Conclusion:

  1. Recovereez Forte capsules exhibited prophylactic activity against SARS-CoV2 when pre-treated with Vero cell line for 1, 2 and 4 hours followed by infection at 0.1 Mol with an ECso value of 46.5 Hg/ml, 34.9 pug/ml and 19.9 pug/ml and Selectivity index (SI) value of o.90,1.20 and 2.10 respectively.
  2. Recovereez Forte capsules exhibited therapeutic activity when treated with cells infected with SARS-CoV2 virus (0.1 Mol) 1 hour, 2 hour and 4 hour post infection with an EC5o value of 20.4 ng/ml, 21.5 pug/ml and 19.3 Hg/ml with a Selectivity index (SI) value of 2.05,1.95 and 2.16 respectively.
  3. Recovereez Forte capsules when incubated with SARS-CoV2 virus (0.1 Mol) for, 2 hour exhibited virucidal activity against SARS-CoV2 with an EC5o value of 1133.0 pug/ml and Selectivity index (SI) value of o.04.
Know More
Centre for Cellular and Molecular Biology (CCMB)

Anti-viral Testing Report

Specifics of Product: Drug Molecule
Name of the virus tested: SARS-CoV-2

Results:

  1. The molecule showed 75% reduction at 500μg/ml. The viral particle reduced from 106.7 to 106.1
Know more
Non-Clinical Study Reports
  1. Acute Oral Toxicity of Recovereez Forte in Rats
  2. RGCB Pseudovirion Assay Report
  3. In Vitro Anti-Inflammatory Action- Test Report
  4. In Vitro Cytotoxicity – Test Report
  5. Evaluation of Recovereez Forte capsules by NIBEC
  6. Molecular Docking – Final Report
  7. Anti-viral Testing Report -CCMB
  8. Acute Oral Toxicity Study Of Recovereez (Capsules) In Wistar Albino Rats
  9. Acute oral toxicity of Recovereez capsules in Wistar rats – Histopathological analysis
Know More